BACKGROUND: Myeloid-derived suppressor cells (MDSCs) are a population of immature immune cells with several protumorigenic functions. CD38 is a transmembrane receptor-ectoenzyme expressed by MDSCs in murine models of esophageal cancer. We hypothesized that CD38 could be expressed on MDSCs in human colorectal cancer (CRC), which might allow for a new perspective on therapeutic targeting of human MDSCs with anti-CD38 monoclonal antibodies in this cancer. METHODS: Blood samples were collected from 41 CRC patients and 8 healthy donors, followed by peripheral blood mononuclear cell (PBMC) separation. Polymorphonuclear (PMN-) and monocytic (M-) MDSCs and CD38 expression levels were quantified by flow cytometry. The immunosuppressive capacity of M-MDSCs from 10 CRC patients was validated in a mixed lymphocyte reaction (MLR) assay. RESULTS: A significant expansion of CD38+ M-MDSCs and a trend of expansion of CD38+ PMN-MDSCs (accompanied by a trend of increased CD38 expression on both M- and PMN-MDSCs) were observed in PBMCs of CRC patients when compared with healthy donors. The CD38+ M-MDSCs from CRC patients were found to be immunosuppressive when compared with mature monocytes. CD38+ M- and PMN-MDSC frequencies were significantly higher in CRC patients who previously received treatment when compared with treatment-naive patients. CONCLUSIONS: This study provides a rationale for an attempt to target M-MDSCs with an anti-CD38 monoclonal antibody in metastatic CRC patients. FUNDING: NCI P01-CA14305603, the American Cancer Society, Scott and Suzi Lustgarten Family Colon Cancer Research Fund, Hansen Foundation, and Janssen Research and Development.
BACKGROUND: Myeloid-derived suppressor cells (MDSCs) are a population of immature immune cells with several protumorigenic functions. CD38 is a transmembrane receptor-ectoenzyme expressed by MDSCs in murine models of esophageal cancer. We hypothesized that CD38 could be expressed on MDSCs in humancolorectal cancer (CRC), which might allow for a new perspective on therapeutic targeting of human MDSCs with anti-CD38 monoclonal antibodies in this cancer. METHODS: Blood samples were collected from 41 CRC patients and 8 healthy donors, followed by peripheral blood mononuclear cell (PBMC) separation. Polymorphonuclear (PMN-) and monocytic (M-) MDSCs and CD38 expression levels were quantified by flow cytometry. The immunosuppressive capacity of M-MDSCs from 10 CRC patients was validated in a mixed lymphocyte reaction (MLR) assay. RESULTS: A significant expansion of CD38+ M-MDSCs and a trend of expansion of CD38+ PMN-MDSCs (accompanied by a trend of increased CD38 expression on both M- and PMN-MDSCs) were observed in PBMCs of CRC patients when compared with healthy donors. The CD38+ M-MDSCs from CRC patients were found to be immunosuppressive when compared with mature monocytes. CD38+ M- and PMN-MDSC frequencies were significantly higher in CRC patients who previously received treatment when compared with treatment-naive patients. CONCLUSIONS: This study provides a rationale for an attempt to target M-MDSCs with an anti-CD38 monoclonal antibody in metastatic CRC patients. FUNDING: NCI P01-CA14305603, the American Cancer Society, Scott and Suzi Lustgarten Family Colon Cancer Research Fund, Hansen Foundation, and Janssen Research and Development.
Entities:
Keywords:
Cancer; Cancer immunotherapy; Colorectal cancer; Gastroenterology; Oncology
Authors: Michel de Weers; Yu-Tzu Tai; Michael S van der Veer; Joost M Bakker; Tom Vink; Daniëlle C H Jacobs; Lukas A Oomen; Matthias Peipp; Thomas Valerius; Jerry W Slootstra; Tuna Mutis; Wim K Bleeker; Kenneth C Anderson; Henk M Lokhorst; Jan G J van de Winkel; Paul W H I Parren Journal: J Immunol Date: 2010-12-27 Impact factor: 5.422
Authors: Xiaoyan Feng; Li Zhang; Chirag Acharya; Gang An; Kenneth Wen; Lugui Qiu; Nikhil C Munshi; Yu-Tzu Tai; Kenneth C Anderson Journal: Clin Cancer Res Date: 2017-03-01 Impact factor: 12.531
Authors: Paul A Blair; Lina Yassin Noreña; Fabian Flores-Borja; David J Rawlings; David A Isenberg; Michael R Ehrenstein; Claudia Mauri Journal: Immunity Date: 2010-01-14 Impact factor: 31.745
Authors: Vincenzo Bronte; Sven Brandau; Shu-Hsia Chen; Mario P Colombo; Alan B Frey; Tim F Greten; Susanna Mandruzzato; Peter J Murray; Augusto Ochoa; Suzanne Ostrand-Rosenberg; Paulo C Rodriguez; Antonio Sica; Viktor Umansky; Robert H Vonderheide; Dmitry I Gabrilovich Journal: Nat Commun Date: 2016-07-06 Impact factor: 14.919
Authors: Luca Cassetta; Kirsten Bruderek; Joanna Skrzeczynska-Moncznik; Oktawia Osiecka; Xiaoying Hu; Ida Marie Rundgren; Ang Lin; Kim Santegoets; Utku Horzum; Ana Godinho-Santos; Gennadiy Zelinskyy; Thalia Garcia-Tellez; Sunčica Bjelica; Bartłomiej Taciak; Astrid Olsnes Kittang; Benedikt Höing; Stephan Lang; Michael Dixon; Verena Müller; Jochen Sven Utikal; Derya Karakoç; Kerim Bora Yilmaz; Emilia Górka; Lubomir Bodnar; Olympia Evdoxia Anastasiou; Christine Bourgeois; Robert Badura; Monika Kapinska-Mrowiecka; Mirjana Gotic; Mark Ter Laan; Esther Kers-Rebel; Magdalena Król; Juan Francisco Santibañez; Michaela Müller-Trutwin; Ulf Dittmer; Ana Espada de Sousa; Güneş Esendağlı; Gosse Adema; Karin Loré; Elisabeth Ersvær; Viktor Umansky; Jeffrey W Pollard; Joanna Cichy; Sven Brandau Journal: J Immunother Cancer Date: 2020-09 Impact factor: 13.751
Authors: Samantha M Y Chen; Alexandra L Krinsky; Rachel A Woolaver; Xiaoguang Wang; Zhangguo Chen; Jing H Wang Journal: Mol Carcinog Date: 2020-02-03 Impact factor: 4.784
Authors: Christina Guo; Mateus Crespo; Bora Gurel; David Dolling; Jan Rekowski; Adam Sharp; Antonella Petremolo; Semini Sumanasuriya; Daniel N Rodrigues; Ana Ferreira; Rita Pereira; Ines Figueiredo; Niven Mehra; Maryou B K Lambros; Antje Neeb; Veronica Gil; George Seed; Leon Terstappen; Andrea Alimonti; Charles G Drake; Wei Yuan; Johann S de Bono Journal: Eur Urol Date: 2021-03-05 Impact factor: 20.096